Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561038 | 0.81 | PTPN5 (0.67) | KIF11PTPN5ALDH1A1TSHRKDM4E | |
| SCHEMBL27799156 | 0.81 | PTPN5 (0.43) | KIF11PTPN5ALDH1A1KDM4EMAPT | |
| SCHEMBL17840160 | 0.80 | KIF11 (0.68) | KIF11BACE1MAOBALDH1A1TSHR | |
| SCHEMBL6638725 | 0.79 | KIF11 (0.47) | KIF11PTPN5BACE1ALDH1A1TSHR | |
| SCHEMBL2795998 | 0.79 | PTGS2 (0.47) | PTPN5MAOBALDH1A1MAPTESR2 | |
| SCHEMBL57735 | 0.78 | ALDH1A1 (0.42) | BACE1ALDH1A1HSD17B10ESR2TDP1 | |
| SCHEMBL8025255 | 0.78 | KIF11 (0.65) | KIF11BACE1MAOBALDH1A1TSHR | |
| SCHEMBL6676673 | 0.76 | KDM1A (0.41) | KIF11BACE1MAPT | |
| SCHEMBL224641 | 0.76 | CASP3 (0.42) | BACE1ALDH1A1HSD17B10MAPTESR2 | |
| SCHEMBL11310344 | 0.76 | KIF11 (0.77) | KIF11PTPN5BACE1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482368-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1404653-B1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7348355-B2 | Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate | PFIZER INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| US-6979692-B2 | such as (S)-1-ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid-[2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]amide; for treatment of obesity and lipid disorders; diabetes | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-6949572-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-04-14 | — | — | US | disclosed |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| US-6720351-B2 | 1H-INDOLE-2-CARBOXYLIC ACID (2-(BENZYL(METHYL)AMINO) -2-OXO-1-PHENYLETHYL)AMIDES; TRIAMIDE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND APOLIPOPROTEIN B (APO B) INHIBITORS; OBESITY; ANTILIPEMIC AGENTS | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003002533-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PRODUCTS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-0902785-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING 4'-TRIFLUOROMETHYLBIPHENYL-2-CARBOXYLIC ACID 2-(2H- 1,2,4]TRIAZOL-3-YLMETHYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL]-AMIDE | PFIZER (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5998623-A | Process and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid [2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-a mide | PFIZER INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0902785-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING 4'-TRIFLUOROMETHYLBIPHENYL-2-CARBOXYLIC ACID 2-(2H- 1,2,4]TRIAZOL-3-YLMETHYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL]-AMIDE | PFIZER INC. (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1997041111-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING 4'-TRIFLUOROMETHYLBIPHENYL-2-CARBOXYLIC ACID [2-(2H-[1,2,4]TRIAZOL-3-YLMETHYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL]-AMIDE | PFIZER INC. (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | KIF11 4629/4885PTPN5 809/4885BACE1 1488/4885 |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | KIF11 4628/4885PTPN5 938/4885BACE1 643/4885 |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | KIF11 4629/4885PTPN5 809/4885BACE1 1488/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | KIF11 4628/4885PTPN5 938/4885BACE1 643/4885 |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | KIF11 4674/4885PTPN5 741/4885BACE1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.